Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/08—Peptides having 5 to 11 amino acids
  • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
  • A61P5/36—Antigestagens

Definitions

• Endometriosis is the ectopic presence of endometrial type glands and stro a in sites which are outside of the uterus. This ectopic occurrence of endometrial tissue frequently forms cysts containing altered blood. The condition results in debilitating pain for millions of women worldwide and particularly occurs in conjunction with the monthly proliferation of endometrial tissue. Endometriosis is frequently a lifelong condition.
• Endometriosis can be treated by a variety of medical therapies but none of these are sufficiently effective for a long term treatment beyond six months or more.
• the oldest therapy with a demonstrable effect is the administration of progestin either by injection, orally or in combination with oral contraceptives.
• long term administration of progestins, especially androgenic ones have been associated with a number of undesirable side effects and has not received regulatory approval in the United States.
• a synthetic steroid derived from ethisterone, namely l7-c--pregna-2,4-dien-20-yno[2,3-d]-isoxazol-17-ol, also known as danazol and marketed under the trademark Danocrine has been shown an effective medication for the treatment of endometriosis producing a hypoestrogenic milieu. Unfortunately, this drug also has many androgenic side effects.
• estrogen depravation In addition to the vasomotor flush of estrogen depravation, it causes weight gain, long muscle cramps, breast atrophy, hot flashes, mood swings, oily skin, depression, edema, acne, fatigue, hirsutism, alterations in the libido, headache, rash and a deepening of the voice.
• endometriosis One of the most effective treatments of endometriosis is the administration of a gonadotropin releasing hormone agonist which suppresses pituitary gonadotropin secretion and therefore induces a state of reversible pseudomenopause. Although individual response varies, endometriosis usually quickly regresses within only three months of initiation of therapy. On withdrawal of the treatment, pain often returns and the endometriosis reappears several months after the return of normal menstrual cycles.
• the drug can also be used to treat uterine fibroid tumors (leiomyomata) .
• the main drawback of this therapy is a series of side effects stemming from protracted severe hypoestrogenism or the pseudomenopausal state induced by severe estrogen deprivation, namely hot flashes, bone loss and loss of cardiovascular protection by estrogen.
• the object of hormone replacement therapy is to provide estrogen and/or progestin and thereby prevent bone loss. While individual response again varies, the bone loss generally begins to be measurable after about 3 months of therapy and becomes highly significant after about 6 months of therapy in the most vulnerable patients.
• the total unacceptability of this side effect from a risk- benefit point of view is apparent from the fact that the mortality index is about 3.2 years after a post- menopausal woman experiences a break of the hip bones due to osteoporosis.
• PMS Premenstrual syndrome
• DRB dysfunctional uterine bleeding
• a combination of a gonadotropin releasing hormore agonist (leuprolide) and progestin (medoxyprogesterone acetate) in the treatment of uterine leiomyomata.
• progestin was noted to reverse the effectiveness of the agonist-induced hypoestrogesism in decreasing nonmyoma volume, i.e., the treatment prevented the beneficial effects of the agonist treatment.
• Figure 1 is a graph of mean daily serum estradiol.
• Figure 2 is a graph of perionateal endometriosis resulting from various treatment regiments.
• Figure 3 is a graph of bone mineral density as a result of various treatment regiments.
• This invention broadly relates to the treatment of ovarian estrogen dependent conditions such as endometriosis, myoma tumors (e.g., uterine leiomyomata), PMS and/or DUB. More particularly, it relates to a method of treating an ovarian estrogen dependent condition by administering a gonadotropin releasing hormone analog for a period of time of at least about 30 days which is sufficient to lower the circulating serum estrogen level to approximately 20 pg/ml or less and thereafter administering an endometrium anti- proliferative and bone conserving amount of antiprogestin.
• ovarian estrogen dependent conditions such as endometriosis, myoma tumors (e.g., uterine leiomyomata), PMS and/or DUB. More particularly, it relates to a method of treating an ovarian estrogen dependent condition by administering a gonadotropin releasing hormone analog for a period of time of at least about 30 days which is sufficient to lower the circulating serum estrogen level to approximately 20 p
• a woman suffering from an ovarian estrogen dependent condition such as endometriosis, uterine leiomyomata, PMS and/or DUB is treated, in accordance with the present invention, with both a gonadotropin releasing hormone analog and an antiprogestin.
• Gonadotropin releasing hormone is a small polypeptide produced in the hypothalamus and is sometimes termed gonadotropic releasing hormone, lutenizing hormone releasing hormone, GnRH or LHRH. Any analog, whether an antagonist or agonist, of this polypeptide can be used in the present invention. Examples of gonadotropin releasing hormone antagonist can be found, inter alia, in United States Patents 4,409,208, 4,547,370, 4,565,804, 4,569,927 and 4,619,914, 5,198,533 and WO 89/01944, the disclosures of which are incorporated herein by reference.
• Antide a decapeptide represented by the formula D-Ac-D-2-Nal'-DpClPhe 2 -D-3- Pal 3 -Ser 4 -NiLys 5 -D-NicLys 6 -Leu 7 -ILys 8 -Pro 9 -D-Ala 10
• Antide a decapeptide represented by the formula D-Ac-D-2-Nal'-DpClPhe 2 -D-3- Pal 3 -Ser 4 -NiLys 5 -D-NicLys 6 -Leu 7 -ILys 8 -Pro 9 -D-Ala 10
• Antide a decapeptide represented by the formula D-Ac-D-2-Nal'-DpClPhe 2 -D-3- Pal 3 -Ser 4 -NiLys 5 -D-NicLys 6 -Leu 7 -ILys 8 -Pro 9 -D-Ala 10
• gonadotropin releasing hormone agonists examples include leuprolide, nafarelin, buserelin,
• the gonadotropin releasing hormone analogs employed in the present invention can be administered in the form of pharmaceutically acceptable non-toxic salts or complexes.
• the salts include acid addition salts such as for instance hydrochloride, hydrobromide, sulfate, phosphate, nitrate, oxalate, fumarate, gluconate, tannate, maleate, acetate, benzoate, succinate, alginate, malate, ascorbate, tartrate and the like.
• the complexes can be with metals such as for example zinc, barium, calcium, magnesium, aluminum and the like.
• the gonadotropin releasing hormone releasing hormone analog aspect of the present invention is similar to the previous use of such analogs for the treatment of endometriosis and/or uterine leiomyomata.
• the route of administration can be any conventional route where the analog is active, for instance orally, intravenously, ⁇ ubcutaneously, intramuscularly, sublingually, percutaneously, rectally, intranasally or intravaginally.
• the administration form can be a tablet, dragee, capsule, pill, nasal mist, aerosol, pellet, implant (or other depot) and the like.
• the amount of gonadotropin releasing hormone analog administered is that sufficient to lower circulating estrogen to about 20 pg/ml or below by the end of a time period of about 1 to 6 months and is similar to that practiced heretofore. Broadly the amount can be in the range of about 0.05 to 50 mg, preferably about 0.5 to 10.0 mg daily.
• the determination of an effective dose is a routine exercise in the pharmaceutical arts, taking various physical parameters such as weight, age and the like into account, and is best determined by the attending clinician.
• the administration can be periodic, such as on a monthly basis or continuous such as on a daily basis. Daily administration is preferred because individuals are more likely to follow the treatment regimen and not to forget or overlook a periodic administration schedule.
• the use of a depot administration such as the employment of leuprolide acetate commercially available under the trademark Lupron Depot, can be convenient.
• the antiprogestin to be combined with GnRH agonist or GnRH antagonist can be a progesterone receptor antagonist or a pharmaceutically suitable agent that counteracts the normal biological activity of progesterone.
• a preferred antiprogestin is a progesterone receptor antagonist, either steroidal or non-steroidal, that manifests some capacity to diminish estrogen secretion but more importantly, blocks estrogen stimulation of the tropic tissues such as endometriosis, ectopic or in the uterus, or leiomyomata tissue.
• RU 486 is particularly suitable in the practice of this invention. Examples of antiprogestins which can be employed in this invention are RU 486 ("mifepristone", Roussel Uclaf, Paris; U.S.
• the antiprogestin can be administered by way of any art recognized means as practiced in the pharmaceutical arts.
• a ⁇ suitable antiprogestin may be so formulated so that it can be administered orally, subcutaneously, intramuscularly, buccally, via a skin patch for transdermal absorption, contained within an inert matrix which is implanted within the body and in the depot state or intravaginally in a matrix that slowly releases the antiprogestin (such an implant is taught in U.S. Patent Nos. 4,957,119 and 5,088,505 and the like).
• compositions containing the antiprogestin and a suitable carrier can be solid dosage forms which includes tablets, capsules, cachets, pellets, pills, powders or granules; topical dosage forms which includes solutions, powders, fluid emulsions, fluid suspensions, semi-solids, ointments, pastes, creams, gels or jellies and foams; and parenteral dosage forms which includes solutions, suspensions, emulsions or dry powder comprising an effective amount of antiprogestin as taught in this invention.
• the active ingredient, the antiprogestin can be contained in such formulations in addition to pharmaceutically acceptable diluents, fillers, disintegrants, binders, lubricants, surfactants, hydrophobic vehicles, water soluble vehicles, emulsifiers, buffers, humectants, moisturizers, solubilizers, preservatives and other means of augmenting the medicinal entity.
• pharmaceutically acceptable diluents fillers, disintegrants, binders, lubricants, surfactants, hydrophobic vehicles, water soluble vehicles, emulsifiers, buffers, humectants, moisturizers, solubilizers, preservatives and other means of augmenting the medicinal entity.
• the means and methods for administration are known in the art and an artisan can refer to various pharmacologic references for guidance. For example, “Modern Pharmaceutics", Banker & Rhodes, Marcel Dekker, Inc. 1979; “Goodman & Gil-nan's The Pharmaceutical Basis
• the administration of the gonadotropin releasing hormone analog and the anti ⁇ progestin may overlap.
• the two components can be co-administered utilizing the same or different dosage forms or means, for example the same tablet.
• Application of the components, compositions and the methods of this invention for the medical and/or pharmaceutical use which are described in this text can thus be accomplished by any clinical, medical or pharmaceutical methods or techniques as are presently or prospectively known to those skilled in the art.
• the gonadotropin releasing hormone analog is administered for a period of time of at least 30 days which is sufficient to lower the circulating estrogen level in the blood to about 20 picogra s per ml or less and preferably to lower the circulating estrogen level to at least about 10 picograms per ml or below, thereby simulating postmenopausal estrogen levels.
• the analog administration is halted after about 6 months although it is possible this can be extended if a bone conserving amount of antiprogestin administration is begun in timely fashion.
• the preferred present length of administration of GnRH agonist is roughly three months.
• the administration of the antiprogestin is commenced when the circulating estrogen level has fallen to 20 pg/ml or less, and preferably about 10 pg/ml or less.
• the antiprogestin administration period can overlap the gonadotropin releasing hormone analog administration period or can commence on cession of GnRH analog administration or there can be a gap between administration intervals as long as the circulating estrogen level does not remain above about 20 pg/ml.
• the amount of antiprogestin is that which both inhibits estrogenic endometrial proliferation, i.e. an anti- proliferation effective amount, and also is a bone conserving effective amount.
• bone conserving means that the bone mass (density) is either maintained or increased. In the case of the antiprogestin RU 486, this is generally about 0.05 to
• the amount of antiprogestin employed can, as with the gonadotropin releasing hormone analog, be determined by using art recognized methods such as for instance by establishing dose-response curves in suitable primate models having an inherent ovarian menstrual cycle similar to that of women and extrapolating to humans, extrapolating from suitable in vitro systems or determining effectiveness in clinical trials.
• the attending clinician will taken weight, age and other physical and medical parameters into account when establishing an appropriate dosage amount.
• the gonadotropin releasing hormone agonist selected was leuprolide acetate
• the anti-progestin selected was RU 486 and these were administered to female cynomolgus monkeys, which are recognized to be a highly desirable model for human research. Thirty-six adult female cynomolgus monkeys
• a 2 cm fundal hysterotomy was performed and approximately 100 mg of endometrium removed by curettage and minced in sterile 0.9% saline.
• the uterine incision was closed with 4-0 vicryl suture.
• the minced endometrial tissue was injected sub- peritoneally into five sites, namely, the left and right vesicouterine fold, right and left broad ligaments, and the cul-de-sac.
• Group 1 was given monthly injections of the gonadotropin releasing hormone agonist, in an amount of 80 ⁇ g/kg im on menstrual day 21 of the second laparotomy cycle. This was continued at 28 day intervals for a total of 3 injections, at which time weekly injections of the antiprogestin RU 486 began, (5 mg/kg i , in oil, initially, then 2 mg/kg/week) . RU 486 was continued for a period of 24 weeks.
• Group 2 was given weekly im injections of RU 486 alone (5 mg/kg initially, then 2 mg/kg/week) beginning on menstrual day 1 of the cycle after the endometriosis was confirmed. This was continued for a treatment period of 36 weeks.
• Group 3 was given doses of the GnRH analog alone for 36 weeks.
• Group 4 was a control and received vehicle, 0.5 ml of normal saline im, weekly for 36 weeks.
• the monkeys were examined daily on morning rounds. Changes in behavior were noted. Skin was examined for signs of rash or inflammatory changes at the injection site. The perineum was examined for signs of menses. Body weight was determined monthly, and changes in appetite noted. Urine was collected at the time of blood sampling. The first sample was taken at the time of the first laparotomy and the second sample was taken at the time of the first injection with subsequent samples drawn every four weeks from the time of the second urine sample. Dual X-ray absorptiometry (DXA, Norland) was used to measure the bone mineral density of the lumbar spine. Primates were anesthetized with ketamine and restrained to minimize motion artifact. DXA was performed before injections began and at three month intervals until completion of the study. At the time of each laparotomy, a small repeat hysterotomy was performed for the purpose of endometrial sampling for histologic examination.
• DXA Dual X-ray absorptiometry
• the area of ectopic endometrium visualized on peritoneal surfaces is shown in Figure 2.
• the pre- treatment areas for all groups were similar (ANOVA, p>0.1).
• the post-treatment area was significantly different from pre-treatment areas for groups 1, 2 and 3, and from the post-treatment area in the control, group 4 (Wilcoxon, p ⁇ 0.05).
• This observation shows that both GnRH analog and antiprogestin had an unequivocal limiting impact on the size of the endometrial implants.
• Group 1 where the primates were switched to RU 486 for three months after completing the course of GnRH analog therapy, the mean area of peritoneal disease remained the unchanged.
• the GnRH analog exposed endometrium was uniformly thin and weakly proliferative.
• the antiprogestin exposed endometrium was thinner than in control monkeys, but consistently appeared to be interval phase, such as day 17 in a typical normal menstrual cycle.
• Control treatment primates had cycling endometrium, thicker on all biopsy days than either of the other groups.
• the thickness of the vaginal epithelium, the keratin layer, and to the base of the rete pegs, were both greater in the antiprogestin group than in the GnRH analog groups.
• the findings in the control group were variable, but the keratin layer was thicker than after GnRH analog treatment.
• Ectopic endometriotic lesions like in situ endometrium, undergo gradual regression during three months of therapy with endometrial changes occurring more rapidly during gonadotropin releasing hormone analog treatment than with antiprogestin alone.
• the above results demonstrate that the antiprogestin was able to sustain the reduced surface of peritoneal endometriosis after discontinuing the analog treatment period.
• Endometriosis in the control primates did not improve spontaneously and indeed, the endometriotic lesions worsened progressively over three months.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Endocrinology (AREA)
• Organic Chemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Reproductive Health (AREA)
• Epidemiology (AREA)
• Immunology (AREA)
• Diabetes (AREA)
• Gastroenterology & Hepatology (AREA)
• Urology & Nephrology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)
• Steroid Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (21)

Applications Claiming Priority (2)

Publications (1)

Family

ID=22706258

Family Applications (1)

Country Status (29)

Cited By (27)

Families Citing this family (14)

Family Cites Families (9)

• 1994
  • 1994-02-04 US US08/191,631 patent/US5681817A/en not_active Expired - Fee Related
• 1995
  • 1995-02-02 CZ CZ19962103A patent/CZ291709B6/cs not_active IP Right Cessation
  • 1995-02-02 WO PCT/US1995/001479 patent/WO1995020972A1/en not_active Ceased
  • 1995-02-02 FI FI963036A patent/FI963036L/fi not_active IP Right Cessation
  • 1995-02-02 MD MD96-0323A patent/MD1432C2/ro unknown
  • 1995-02-02 RO RO96-01583A patent/RO117420B1/ro unknown
  • 1995-02-02 DE DE69509544T patent/DE69509544T2/de not_active Expired - Fee Related
  • 1995-02-02 CA CA002182183A patent/CA2182183C/en not_active Expired - Fee Related
  • 1995-02-02 JP JP07520794A patent/JP3130048B2/ja not_active Expired - Fee Related
  • 1995-02-02 EP EP95910179A patent/EP0785792B1/en not_active Expired - Lifetime
  • 1995-02-02 RU RU96118109A patent/RU2110274C1/ru active
  • 1995-02-02 BR BR9506606A patent/BR9506606A/pt not_active Application Discontinuation
  • 1995-02-02 CN CN95192252A patent/CN1144486A/zh active Pending
  • 1995-02-02 HU HU9601969A patent/HUT74622A/hu unknown
  • 1995-02-02 ES ES95910179T patent/ES2132645T3/es not_active Expired - Lifetime
  • 1995-02-02 AT AT95910179T patent/ATE179610T1/de not_active IP Right Cessation
  • 1995-02-02 TJ TJ96000402A patent/TJ242B/xx unknown
  • 1995-02-02 KR KR1019960704226A patent/KR970700507A/ko not_active Ceased
  • 1995-02-02 AP APAP/P/1996/000840A patent/AP724A/en active
  • 1995-02-02 PL PL95315792A patent/PL178273B1/pl not_active IP Right Cessation
  • 1995-02-02 NZ NZ281441A patent/NZ281441A/en unknown
  • 1995-02-02 DK DK95910179T patent/DK0785792T3/da active
  • 1995-02-02 SK SK962-96A patent/SK96296A3/sk unknown
  • 1995-02-02 AU AU18386/95A patent/AU689229B2/en not_active Ceased
• 1996
  • 1996-07-29 OA OA60870A patent/OA10777A/en unknown
  • 1996-08-01 BG BG100766A patent/BG62238B1/bg unknown
  • 1996-09-03 LV LVP-96-354A patent/LV11782B/en unknown
  • 1996-09-04 LT LT96-133A patent/LT4182B/lt not_active IP Right Cessation
• 1999
  • 1999-05-07 GR GR990401145T patent/GR3030164T3/el unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events